Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan - Takeaways - MDSpire

Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan

  • By

  • Ruba Al Abweh

  • Sarah Al Sharie

  • Nabil Hasasna

  • Nisreen Amayiri

  • Mouness Obeidat

  • Maysa Al-Hussaini

  • July 17, 2026

Share

  • 1

    Molecular profiling is essential for CNS tumor diagnosis and treatment, as emphasized by the 2021 WHO Classification.

  • 2

    A retrospective review at KHCC involved 105 patients who underwent outsourced molecular testing to SickKids in Canada.

  • 3

    Outsourced testing yielded a 92% conclusive result rate, with the highest in medulloblastoma and the lowest in ependymoma.

  • 4

    The median turnaround time for molecular testing was 26 days, with a total expenditure of 153,506 US Dollars.

  • 5

    Outsourcing molecular diagnostics is feasible and impactful in limited-resource settings, aiding in accurate diagnoses and identifying actionable targets.

Original Source(s)

Access to molecular diagnostics for CNS tumors through international outsourcing: experience from Jordan

  • by Ruba Al Abweh, Sarah Al Sharie, Nabil Hasasna, Nisreen Amayiri, Mouness Obeidat, Maysa Al-Hussaini

  • July 17, 2026

Related Content

Research progress of small molecule targeted drugs for non-small cell lung cancer

Intravascular large B-cell lymphoma masked by multinodular goiter of the thyroid: a case report and diagnostic pitfall

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions